Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs nalbuphine for prevention of postoperative shivering in renal transplant recipients
ChiCTR2600120709Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Mar 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexmedetomidine and nalbuphine in postanesthetic shivering (PAS) (3 arms), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Incidence of postoperative shivering in PACU (Wrench scale grade >= 1). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
dexmedetomidinenalbuphine
03
Conditions
postanesthetic shivering (PAS)
Beyond the preview
Go deeper on ChiCTR2600120709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120709.